Navigation Links
Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
Date:2/2/2009

ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today that Richard Garr, CEO and President, will present at the 11th Annual BIO CEO & Investor Conference to be held on February 9-10, 2009, at the Waldorf=Astoria Hotel, New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO)

Neuralstem's presentation is scheduled for Monday, February 9, 2009 at 10:00 a.m. Eastern Time.

The presentation will be webcast live and will be available on the Investor Relations section of Neuralstem's website at www.neuralstem.com. For those who are not available to listen to the live broadcast, the call will be archived.

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS). The Company filed an IND (Investigational New Drug) application with the FDA for ALS clinical trials in December, 2008, and has entered into a collaborative agreement with Albert-Ludwigs-University, in Freiburg, Germany, to develop clinical trials for Huntington's disease.

In pre-clinical work, the company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
2. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
3. Neuralstem Reports Second Quarter Financial Results and Highlights
4. Neuralstem Fills Key Product Development Position
5. Neuralstem Responds to New StemCells, Inc. Lawsuit
6. Neuralstem Sues StemCells, Inc. Over New Patent
7. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
8. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
9. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
10. Neuralstem Shares Accepted for Trading on Amex(R)
11. The EntreTech Forum Presents... Greening Of America - The Conversion of Bio-Agriculture, Bio-Energy, and Bio-Products to Eco-Sustainable Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, ... Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ... to deliver therapeutic levels of olanzapine for a period of 3 months., “We are ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... the deadline to participate in its previously announced ... consisting of shares of common stock and Series ... holders of listed warrants. As ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
Breaking Biology Technology:
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
(Date:2/7/2017)... WARSAW, Ind. , Feb. 7, 2017 ... global leader in musculoskeletal healthcare, will present at the ... Lotte New York Palace Hotel on Wednesday, February 15, ... A live webcast of the presentation can be accessed ... for replay following the conference via Zimmer Biomet,s Investor ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
Breaking Biology News(10 mins):